{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:52:05Z","timestamp":1775274725012,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.neuropharm.2019.03.033","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T11:11:23Z","timestamp":1553944283000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6\/2 mouse model"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9994-433X","authenticated-orcid":false,"given":"Robert B.","family":"Laprairie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1850-5686","authenticated-orcid":false,"given":"Amina M.","family":"Bagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian L.","family":"Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Zrein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie E.M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sinal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushkar M.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh A.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen M.","family":"Denovan-Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.03.033_bib1","article-title":"Positive allosteric modulators of CB1 receptors","volume":"vol. 86","author":"Adam","year":"2007"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchemneu.2009.02.001","article-title":"Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease","volume":"37","author":"Allen","year":"2009","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejphar.2013.09.002","article-title":"Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes","volume":"721","author":"Bagher","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib5","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/cdd.2015.11","article-title":"The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K\/Akt\/mTORC1\/BDNF pathway","volume":"22","author":"Bl\u00e1zquez","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/7854_2013_256","article-title":"Mouse models of Huntington's disease","volume":"22","author":"Brooks","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1089\/jop.2017.0037","article-title":"The in vivo effects of the CB1-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice","volume":"33","author":"Cairns","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib9","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1210\/en.2012-1405","article-title":"Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice","volume":"153","author":"Cardinal","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib10","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1073\/pnas.1400988111","article-title":"A restricted population of CB1 cannabinoid receptors with neuroprotective activity","volume":"111","author":"Chiarlone","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.nbd.2011.12.017","article-title":"Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease","volume":"45","author":"Chiodi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbi.2012.01.004","article-title":"Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis","volume":"26","author":"Cluny","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.tips.2017.05.010","article-title":"Applying structure-based drug design approaches to allosteric modulators of GPCRs","volume":"38","author":"Congreve","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","article-title":"Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice","volume":"98","author":"Denovan-Wright","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jnr.21636","article-title":"Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6\/1 mice","volume":"86","author":"Denovan-Wright","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/hmg\/10.2.145","article-title":"Abnormalities in the functioning of adipocytes from R6\/2 mice that are transgenic for the Huntington's disease mutation","volume":"10","author":"Fain","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fncel.2014.00295","article-title":"Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease","volume":"8","author":"Francelle","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","article-title":"In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569","volume":"25","author":"Gamage","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2017.08.008","article-title":"The great divide: separation between in vitro and in vivo effects of PSNCBAM-1-based CB1 receptor allosteric modulators","volume":"125","author":"Gamage","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejn.12045","article-title":"Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models","volume":"37","author":"Horne","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib25","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/npp.2015.148","article-title":"A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with No psychoactive effects","volume":"40","author":"Ignatowska-Jankowska","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nmeth978","article-title":"A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer","volume":"3","author":"James","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib28","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.drudis.2014.03.016","article-title":"Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis","volume":"19","author":"Kumar","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2013.04.006","article-title":"Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease","volume":"72","author":"Laprairie","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib31","doi-asserted-by":"crossref","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","article-title":"Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons","volume":"289","author":"Laprairie","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2013.12.008","article-title":"The cytokine and endocannabinoid systems are co-regulated by NF-\u03baB p65\/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients","volume":"267","author":"Laprairie","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib33","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","article-title":"Enantiospecific allosteric modulation of cannabinoid 1 receptor","volume":"8","author":"Laprairie","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nchembio.129","article-title":"Selective blockade of 2-arachidonylglycerol hydrolysis produces cannabinoid behavioral effects","volume":"5","author":"Long","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib37","doi-asserted-by":"crossref","first-page":"e114569","DOI":"10.1371\/journal.pone.0114569","article-title":"Prodromal Huntington disease as a model for functional compensation of early neurodegeneration","volume":"9","author":"Malejko","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.26006","article-title":"Animal models of Huntington's disease for translation to clinic: best practices","volume":"29","author":"Menalled","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099520","article-title":"Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6\/2 and zQ175 mouse models of Huntington's disease","volume":"9","author":"Menalled","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","article-title":"Worsening of Huntington disease phenotype in CB1 receptor knockout mice","volume":"42","author":"Mievis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.phrs.2017.11.019","article-title":"Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons","volume":"129","author":"Mitjavila","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuron.2014.06.030","article-title":"ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6\/2 mice","volume":"83","author":"Naydenov","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.03.033_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2014.08.009","article-title":"Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice","volume":"71","author":"Naydenov","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib46","doi-asserted-by":"crossref","first-page":"21134","DOI":"10.1073\/pnas.1202906109","article-title":"Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor","volume":"109","author":"Pamplona","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","article-title":"Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond","volume":"13","author":"Pertwee","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/hmg\/ddn428","article-title":"Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models","volume":"18","author":"Phan","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib49","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1021\/jm201485c","article-title":"Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor","volume":"55","author":"Piscitelli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib50","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.tips.2007.10.006","article-title":"Allosterism and cannabinoind CB(1) receptors: the shape of things to come","volume":"28","author":"Ross","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.26331","article-title":"Therapeutic advances in Huntington's disease","volume":"30","author":"Shannon","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib53","doi-asserted-by":"crossref","first-page":"16880","DOI":"10.1038\/s41598-017-17275-4","article-title":"Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease","volume":"7","author":"Singer","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib54","first-page":"31761","article-title":"Positive allosteric modulation of cannabinoid receptor type 1suppresses pathological pain without producing tolerance or dependence","volume":"8","author":"Slivicki","year":"2017","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib55","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","article-title":"Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells","volume":"9","author":"Trettel","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","article-title":"Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective","volume":"51","author":"Valor","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.bjp.0706157","article-title":"CB1 cannabinoid receptor-mediated modulation of food intake in mice","volume":"145","author":"Wiley","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.03.033_bib58","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:53:41Z","timestamp":1758437621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819301133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":58,"alternative-id":["S0028390819301133"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6\/2 mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}